Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E14.62 EPS (ttm)4.54 Insider Own0.30% Shs Outstand1.28B Perf Week1.55%
Market Cap84.68B Forward P/E9.53 EPS next Y6.97 Insider Trans-1.47% Shs Float1.26B Perf Month1.62%
Income5.90B PEG4.06 EPS next Q1.70 Inst Own82.50% Short Float1.10% Perf Quarter1.11%
Sales22.32B P/S3.79 EPS this Y-45.60% Inst Trans-0.41% Short Ratio2.05 Perf Half Y-2.61%
Book/sh17.20 P/B3.86 EPS next Y1.80% ROA9.20% Target Price80.51 Perf Year-6.92%
Cash/sh21.87 P/C3.03 EPS next 5Y3.60% ROE26.80% 52W Range60.32 - 79.61 Perf YTD6.09%
Dividend2.52 P/FCF23.59 EPS past 5Y18.10% ROI12.00% 52W High-16.64% Beta1.11
Dividend %3.80% Quick Ratio3.50 Sales past 5Y14.60% Gross Margin78.50% 52W Low10.01% ATR1.33
Employees11000 Current Ratio3.60 Sales Q/Q3.80% Oper. Margin37.10% RSI (14)55.95 Volatility1.47% 1.83%
OptionableYes Debt/Eq1.21 EPS Q/Q32.10% Profit Margin26.40% Rel Volume0.77 Prev Close66.99
ShortableYes LT Debt/Eq1.10 EarningsMay 02 AMC Payout51.20% Avg Volume6.79M Price66.36
Recom2.20 SMA201.66% SMA501.60% SMA200-2.73% Volume5,197,487 Change-0.94%
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Jun-14-19 09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
07:46AM  3 Top Dividend Stocks to Buy in June Motley Fool
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
01:54PM  5 Companies Raising Earnings GuruFocus.com
Jun-12-19 06:38PM  Galapagos Ends Enrollment in Osteoarthritis Study Before Time Zacks
06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
09:30AM  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? Zacks
Jun-11-19 08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
Jun-10-19 07:30AM  GT Biopharma Company Update CNW Group
Jun-09-19 10:12AM  Here's How We Evaluate Gilead Sciences, Inc.'s (NASDAQ:GILD) Dividend Simply Wall St.
Jun-06-19 04:38PM  Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy? Insider Monkey
Jun-05-19 09:44AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks
06:00AM  Gerlach Sees Growth at Gilead MoneyShow
Jun-04-19 03:05PM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
02:12PM  5 Biotech Stocks to Buy Right Now Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 05:04PM  US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag Reuters
03:25PM  US STOCKS-Wall Street falls as Facebook, Alphabet, Amazon drag Reuters
11:00AM  Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO American City Business Journals
09:11AM  Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO Zacks
09:00AM  Kite Announces New Yescarta® Data From ZUMA-1 Business Wire
Jun-02-19 04:13PM  Stocks That Fell to 3-Year Lows in the Week of May 31 GuruFocus.com
Jun-01-19 06:00PM  Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Business Wire
09:32AM  Why Is Gilead (GILD) Down 3% Since Last Earnings Report? Zacks
01:02AM  Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies GlobeNewswire
May-31-19 08:31AM  Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma GlobeNewswire
08:30AM  Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Business Wire
May-30-19 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
May-29-19 04:32PM  GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019) GlobeNewswire
04:30PM  Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019) Business Wire
09:30AM  GILD or ILMN: Which Is the Better Value Stock Right Now? Zacks
08:31AM  Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer Business Wire
May-28-19 05:22PM  Gilead Sciences Slips on Goldman's Downgrade to Sell TheStreet.com
04:18PM  5 Top Stock Trades for Wednesday: GILD, NVDA, AMD InvestorPlace
04:02PM  Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum Zacks
12:23PM  Gilead Sciences Stock Is Dropping After Goldman Sachs Said Its Time to Sell Barrons.com
11:08AM  Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding' Benzinga
09:36AM  Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason Zacks
08:19AM  Grants awarded to 11 Canadian initiatives to support the elimination of chronic hepatitis C infection in high-risk populations CNW Group
06:53AM  10 Top Pot Stocks to Buy InvestorPlace
05:23AM  Temasek Holdings Latest Moves Insider Monkey
May-27-19 09:30AM  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? Zacks
01:24AM  3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million American City Business Journals
May-24-19 12:02PM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
10:53AM  Agenus' (AGEN) Pipeline Progression on Track Amid Competition Zacks
09:56AM  Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary Zacks
09:16AM  5 Best PEG Stocks Suitable for GARP Investors Zacks
May-23-19 06:48PM  10 diabetes drugs Bay Area biotech companies have in the pipeline American City Business Journals
10:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-22-19 09:50AM  Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks
09:41AM  The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy Zacks
07:00AM  New Cambridge VC firm ElevateBio's first investment is a Houston biotech American City Business Journals
May-21-19 04:01PM  Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 Business Wire
02:18PM  Top Stock Reports for Disney, Coca-Cola & Gilead Zacks
07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-20-19 10:18AM  A Look At The Fair Value Of Gilead Sciences, Inc. (NASDAQ:GILD) Simply Wall St.
May-19-19 02:00PM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
09:00AM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
May-17-19 12:29PM  Who Had the Better Quarter: Gilead Sciences or Amgen? Motley Fool
May-16-19 02:49PM  A Leading HIV Drug Is Way Overpriced in the U.S. Bloomberg
10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks
06:00AM  Gilead- A Top Biotech for Turnaround Investors MoneyShow
May-15-19 05:37PM  Influential Women 2019: Top CFO Robin Washington pushes beyond her comfort zone American City Business Journals
05:00PM  Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019 Business Wire
11:07AM  Mallinckrodt Ends Enrollment in Phase III for Terlipressin Zacks
10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks
May-14-19 06:11PM  Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition CNBC
May-13-19 09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
07:00AM  Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks Market Exclusive
May-12-19 09:01AM  Is It Finally Time to Buy Gilead Sciences? Motley Fool
May-10-19 03:27PM  Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1 Zacks
02:54PM  Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss Zacks
10:51AM  PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks
08:34AM  Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks
07:56AM  Drugmaker Gilead reaches multiyear agreement with White House to donate HIV prevention med CNBC
May-09-19 07:24PM  Gilead to donate HIV medication for up to 200,000 Americans a year MarketWatch
07:12PM  Drugmaker will donate meds for US push to end HIV epidemic Associated Press
06:17PM  Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates Zacks
05:11PM  Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic Business Wire
03:21PM  Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1 Zacks
02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
09:30AM  Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year? Zacks
May-08-19 05:39PM  'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong American City Business Journals
02:12PM  Gilead To Invest $109M In Goldfinch Bio For Kidney Drug Collaboration Benzinga
11:30AM  Edited Transcript of GILD earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents
08:34AM  Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases MarketWatch
07:00AM  Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease Business Wire
06:24AM  Model N (MODN) Q2 2019 Earnings Call Transcript Motley Fool
May-07-19 04:57PM  Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks
09:00AM  Where Will Gilead Sciences Spend Its Cash? Motley Fool
May-06-19 04:01PM  Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14 Business Wire
May-05-19 09:15AM  5 Things You Can Expect for Gilead Sciences With Its New CEO at the Helm Motley Fool
May-03-19 04:32PM  Is Gilead Stock Seeing The Light Of O'Day? HIV Drugs Bolster Views Investor's Business Daily
12:58PM  Gilead Sciences Rises on 1st-Quarter Results GuruFocus.com
12:32PM  Stocks making the biggest moves midday: Activision Blizzard, Dish Network, Tesla & more CNBC
11:37AM  Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates Zacks
10:45AM  Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1 Zacks
08:36AM  Gilead Sciences Has Right Prescription on First-Quarter Earnings TheStreet.com
08:00AM  Has Gilead Sciences Turned the Corner? Motley Fool
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM